Metastatic Melanoma Clinical Trials in New York, New York

6 studies are recruiting for metastatic melanoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

   This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (a…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

   Locations

   229 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05136196 on ClinicalTrials.gov

2. A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

   This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   2 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05607095 on ClinicalTrials.gov

3. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

   This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transpl…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

   Locations

   26 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05896839 on ClinicalTrials.gov

4. ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

   The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity o…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Run by

   NYU Langone Health

   See if you can join NCT07504796 on ClinicalTrials.gov

5. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

   This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering (Melanoma/NSCLC), New York, New York

   Locations

   10 in total

   Run by

   Obsidian Therapeutics, Inc.

   See if you can join NCT06060613 on ClinicalTrials.gov

6. A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

   This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   Weill Medical College of Cornell University, New York, New York

   Locations

   11 in total

   Run by

   Iovance Biotherapeutics, Inc.

   See if you can join NCT05361174 on ClinicalTrials.gov